Authors

Latest:

Radiation for Chemo-Sensitization: A Phase II Trial of Cetuximab and Docetaxel With Low-Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck Carcinoma

This study evaluates low dose radiotherapy in combination with docetaxel and cetuximab in patients with recurrent, unresectable squamous cell carcinoma of the head and neck initially treated with definitive chemo-radiation therapy.

Elizabeth Gardner

Latest:

Older Breast Cancer Patients Require Special Consideration

Treating older patients with breast cancer must include more quality of life considerations and different types of survival calculations.

Elizabeth Garner, MD, MPH

Latest:

Dr. Garner Discusses the myRisk Hereditary Cancer Test

Elizabeth Garner, MD, MPH, vice president, Clinical Affairs, Preventive Care, Myriad Genetics, discusses the myRisk Hereditary Cancer Test.

Elizabeth H. Baldini, MD, MPH

Latest:

Dr. Elizabeth H. Baldini on Systemic Therapy for Sarcoma

Elizabeth H. Baldini, MD, MPH, director, radiation oncology, center for sarcoma and bone oncology, associate professor of radiation oncology, Harvard Medical School, discusses sarcoma

Elizabeth J. Shpall, MD

Latest:

Dr. Shpall on Therapeutic Agents for the Treatment of CLL

Elizabeth J. Shpall, MD, professor, deputy department chair, Department of Stem Cell Transplantation, Division of Cancer Medicine, medical director, Cell Therapy Laboratory, director, Cord Blood Bank, the University of Texas MD Anderson Cancer Center, discusses idelalisib and ibrutinib for the treatment of patients with chronic lymphocytic leukemia.

Elizabeth Leick

Latest:

Expert Discusses Value of Venetoclax After BCR Inhibition in CLL

Jeffrey Jones, MD, discusses promising early data for venetoclax in chronic lymphocytic leukemia after progression on BCR-pathway inhibitors, as well as the next steps with the research.

Elizabeth M. Gore, MD

Latest:

Dr. Gore on Toxicity in Elderly Lung Cancer Patients

Dr. Elizabeth Gore, from the Medical College of Wisconsin, on Toxicity in Elderly Lung Cancer Patients

Elizabeth M. Swisher, MD

Latest:

Dr. Swisher on the Limitations of HRD as a Biomarker in Ovarian Cancer

Elizabeth M. Swisher, MD, discusses the limitations of homologous recombination deficiency as a biomarker of response in ovarian cancer based on findings from the phase III VELIA trial.

Elizabeth Mittendorf Dana-Farber

Elizabeth Mittendorf, MD

Latest:

Dr. Mittendorf on Vaccines as Prevention for Breast Cancer

Elizabeth A. Mittendorf, MD, PhD, associate professor in the Department of Surgical Oncology at the University of Texas MD Anderson Cancer Center, discusses the possibility of using vaccines as a preventative measure for breast cancer, particularly to fight recurrence.

Elizabeth Mittendorf, MD, PhD

Latest:

Dr. Mittendorf Discusses Rationale for Updating the AJCC Staging System

Elizabeth Mittendorf, MD, PhD, discusses the rationale for updating the AJCC staging system in patients with breast cancer. This system was originally developed in the 1970s but is still used today.

Elizabeth Petri Henske, MD

Latest:

Dr. Henske on the Potential Role of Glutathione in Chromophobe RCC

Elizabeth Petri Henske, MD, discusses the potential role of glutathione in chromophobe renal cell carcinoma.

Elizabeth Plimack, MD

Latest:

Managing Long-Term Toxicities of Combination Lenvatinib and Pembrolizumab in Advanced RCC

Drs Elizabeth Plimack and Robert Motzer discuss the long-term toxicities of combination lenvatinib/pembrolizumab in patients with advanced RCC, highlighting fatigue, GI discomfort, hand-foot syndrome, liver toxicity, thyroid toxicity, and proteinuria.

Elizabeth R. Plimack, MD, Fox Chase Cancer Center

Elizabeth R. Plimack, MD, MS, FASCO

Latest:

Key Takeaways on Updates in Bladder Cancer

Elizabeth Plimack, MD, MS, FASCO, recaps the discussion with key takeaways on recent updates in bladder cancer.

Elizabeth R. Plimack, MD, MS, Fox Chase Cancer Center

Latest:

Selecting Optimal Therapy for Advanced Non-Clear Cell RCC

Focusing their discussion on a real-world patient scenario, expert panelists discuss treatment options in the setting of advanced non-clear cell renal cell carcinoma.

Elizabeth Swisher, MD

Latest:

Dr. Swisher on the Phase III VELIA Results in Ovarian Cancer

Elizabeth M. Swisher, MD, discusses results from the phase III VELIA/GOG-3005 trial in ovarian cancer.

Elizabeth Whittington

Latest:

Long-term Aspirin Use Decreases Risk of GI Cancers, Especially Colorectal

A recent study joins a body of evidence suggesting that long-term, regular aspirin use is associated with a reduced risk for cancer, with the most dramatic reduction being seen in colorectal cancer incidence.

Ellen K. Ritchie, MD, New York Presbyterian Hospital

Ellen K. Ritchie, MD, Weill Cornell Medicine